214 related articles for article (PubMed ID: 9024174)
1. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg MR; Lo MW; Christ DD; Chiou R; Furtek CI; Amit O; Carides A; Biollaz J; Piguet V; Nussberger J; Brunner HR
Clin Pharmacol Ther; 1997 Jan; 61(1):59-69. PubMed ID: 9024174
[TBL] [Abstract][Full Text] [Related]
2. Acute and chronic effects of losartan (DuP 753) on blood pressure and vascular reactivity in normotensive rats.
Soltis EE; Jewell AL; Dwoskin LP; Cassis LA
Clin Exp Hypertens; 1993 Jan; 15(1):171-84. PubMed ID: 8467311
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
[TBL] [Abstract][Full Text] [Related]
4. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
Ohlstein EH; Gellai M; Brooks DP; Vickery L; Jugus J; Sulpizio A; Ruffolo RR; Weinstock J; Edwards RM
J Pharmacol Exp Ther; 1992 Aug; 262(2):595-601. PubMed ID: 1501114
[TBL] [Abstract][Full Text] [Related]
5. Beta adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT1 receptor antagonist losartan.
Hajj-Ali AF; Wong PC
J Pharmacol Exp Ther; 1993 Dec; 267(3):1423-7. PubMed ID: 7903389
[TBL] [Abstract][Full Text] [Related]
6. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa.
Boulay G; Servant G; Luong TT; Escher E; Guillemette G
Mol Pharmacol; 1992 Apr; 41(4):809-15. PubMed ID: 1569928
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.
Christ DD; Wong PC; Wong YN; Hart SD; Quon CY; Lam GN
J Pharmacol Exp Ther; 1994 Mar; 268(3):1199-205. PubMed ID: 8138932
[TBL] [Abstract][Full Text] [Related]
8. Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in nonhuman primates.
DeGraaf GL; Pals DT; Couch SJ; Lawson JA
J Pharmacol Exp Ther; 1993 Jan; 264(1):6-10. PubMed ID: 8423551
[TBL] [Abstract][Full Text] [Related]
9. Role of AT1 receptors in the central control of sympathetic vasomotor function.
Head GA
Clin Exp Pharmacol Physiol Suppl; 1996; 3():S93-8. PubMed ID: 8993846
[TBL] [Abstract][Full Text] [Related]
10. Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
Wong PC; Timmermans PB
Blood Press Suppl; 1996; 3():11-4. PubMed ID: 8973760
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with angiotensin II receptor antagonists.
Lee RJ; Brunner HR
J Hum Hypertens; 1993 Aug; 7 Suppl 2():S33-6. PubMed ID: 8230087
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):719-25. PubMed ID: 2179531
[TBL] [Abstract][Full Text] [Related]
13. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
Owen RA; Molon-Noblot S; Hubert MF; Siegl PK; Eydelloth RS; Keenan KP
Lab Invest; 1994 Oct; 71(4):543-51. PubMed ID: 7967510
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):726-32. PubMed ID: 2179532
[TBL] [Abstract][Full Text] [Related]
15. Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands.
Keiser JA; Bjork FA; Hodges JC; Taylor DG
J Pharmacol Exp Ther; 1992 Sep; 262(3):1154-60. PubMed ID: 1527720
[TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers.
Duranteau J; Pussard E; Berdeaux A; Giudicelli JF
Br J Clin Pharmacol; 1995 Nov; 40(5):431-8. PubMed ID: 8703646
[TBL] [Abstract][Full Text] [Related]
17. Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD123177 and DuP 753 on proximal nephron and renal transport.
Cogan MG; Liu FY; Wong PC; Timmermans PB
J Pharmacol Exp Ther; 1991 Nov; 259(2):687-91. PubMed ID: 1941617
[TBL] [Abstract][Full Text] [Related]
18. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.
Christ DD
J Clin Pharmacol; 1995 May; 35(5):515-20. PubMed ID: 7657853
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
Cassis LA; Rippetoe PE; Soltis EE; Painter DJ; Fitz R; Gillespie MN
J Pharmacol Exp Ther; 1992 Sep; 262(3):1168-72. PubMed ID: 1527721
[TBL] [Abstract][Full Text] [Related]
20. The diversified pharmacology of angiotensin II-receptor blockade.
Timmermans PB; Smith RD
Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
